Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
October 01, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
September 18, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 14, 2024 16:16 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
August 13, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive Clinical Trial Results at the
2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
August 12, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
August 08, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
July 25, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Showcases Leptomeningeal Metastases Programs
at 2024 SNO/ASCO Conference
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
July 02, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
June 07, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT